Unique Phase I NSCLC Trial Sites Decreasing in United States - Summary - MDSpire
Clinical Guidelines

Unique Phase I NSCLC Trial Sites Decreasing in United States

The number of unique clinical trial sites in the United States with phase I studies for patients with non–small cell lung cancer (NSCLC) decreased by 44% from 2020 to 2024, showing a significant conso...

  • By

  • The ASCO Post Staff

  • May 12, 2026

  • 4 min

Share

A significant decline of 44% in unique clinical trial sites for non–small cell lung cancer (NSCLC) in the U.S. was observed from 2020 to 2024, indicating a trend toward consolidation at top-performing sites. This research, presented at the AACR Annual Meeting 2026, highlights rising concerns over site saturation, contradicting FDA calls for decentralizing trials. With 555 trials opened globally, the majority were in the U.S., where the number of active trial sites dropped from 395 to 223, affecting patient access to diverse clinical research.

Original Source(s)

Unique Phase I NSCLC Trial Sites Decreasing in United States

  • by The ASCO Post Staff

  • May 12, 2026

Related Content

COA and Flatiron Health Study Finds Patients May Experience Longer Survival in Community Oncology Settings

Patients diagnosed with metastatic breast cancer and non–small cell lung cancer had longer survival compared to national benchmarks when treated in independent community oncology practices, according ...

Early-Onset Lung Cancer May Be Connected to Pesticide Contaminants

Dietary patterns in young patients with lung cancer suggest that many have higher dietary quality scores than average U.S. reference values, according to results from a study presented at the American...

This Week’s Biopharma News: Amgen Deepens US Manufacturing Push

The company adds $300 million to its Puerto Rico biologics site as Pfizer reports Phase 3 myeloma data, J&J advances a dual-pathway IBD antibody, and BioNTech streamlines production

  • May 12, 2026

  • 7 min